Labcorp Holdings Inc. $LH Shares Sold by Sequoia Financial Advisors LLC

Key Points

• Sequoia Financial Advisors cut its Labcorp stake by 11.4%, selling 16,467 shares to hold 127,618 shares (~$32.0M), while other institutions made large moves (Goldman Sachs +52.2%, First Trust +83.2%), leaving 95.94% of LH owned by institutional investors.
• Brokerages show a consensus "Moderate Buy" on Labcorp with a consensus price target of $308, and several firms raised targets (JPMorgan to $330; Evercore and Piper Sandler to $300).
• Labcorp beat Q1 estimates with $4.25 EPS versus $4.09 expected and $3.54B revenue, and set FY2026 guidance of 17.700–18.350 EPS.

Sequoia Financial Advisors LLC lowered its position in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 11.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 127,618 shares of the medical research company's stock after selling 16,467 shares during the quarter. Sequoia Financial Advisors LLC owned about 0.15% of Labcorp worth $32,017,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in LH. Brighton Jones LLC acquired a new stake in shares of Labcorp during the 4th quarter worth approximately $991,000. Integrated Wealth Concepts LLC raised its position in shares of Labcorp by 7.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company's stock worth $565,000 after purchasing an additional 177 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Labcorp by 52.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company's stock worth $82,353,000 after purchasing an additional 121,304 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Labcorp during the 2nd quarter worth approximately $5,873,000. Finally, First Trust Advisors LP raised its position in shares of Labcorp by 83.2% during the 2nd quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company's stock worth $22,588,000 after purchasing an additional 39,087 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LH. Evercore reiterated an "outperform" rating and set a $300.00 price target on shares of Labcorp in a research report on Wednesday, April 8th. Wall Street Zen upgraded Labcorp from a "hold" rating to a "buy" rating in a research report on Saturday, May 2nd. Morgan Stanley reiterated an "overweight" rating on shares of Labcorp in a research report on Tuesday, February 17th. Piper Sandler increased their price objective on Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. increased their price objective on Labcorp from $319.00 to $330.00 and gave the stock an "overweight" rating in a report on Wednesday, February 18th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $308.00.

Labcorp Stock Performance

Shares of NYSE LH opened at $257.24 on Thursday. The stock has a fifty day moving average price of $269.63 and a two-hundred day moving average price of $266.97. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. The firm has a market cap of $21.09 billion, a P/E ratio of 22.78, a PEG ratio of 1.80 and a beta of 0.91. Labcorp Holdings Inc. has a 1 year low of $239.67 and a 1 year high of $293.72.

Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.09 by $0.16. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm's quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Research analysts forecast that Labcorp Holdings Inc. will post 17.97 EPS for the current fiscal year.

Labcorp Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp's dividend payout ratio (DPR) is presently 25.51%.

Insider Transactions at Labcorp

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the transaction, the executive vice president directly owned 2,579 shares of the company's stock, valued at approximately $734,782.89. This trade represents a 17.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Brian J. Caveney sold 1,500 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total value of $429,465.00. Following the transaction, the executive vice president directly owned 30,107 shares of the company's stock, valued at approximately $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 16,113 shares of company stock valued at $4,547,450. Company insiders own 0.84% of the company's stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.